The first attempts at measuring soluble APP-derived fragment in the CSF of AD patients were carried out by D. Selkoe and S. Younkin [138] and B. Frangione [139] labs, determining the reduction of soluble APP (sAPP) fragments in the CSF of AD patients. The gene discussed is APP; the disease is Alzheimer disease.